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ABSTRACT
Objective: Prior studies have shown improved neurocognition with initiation of antiretroviral treat-
ment (ART) in HIV. We hypothesized that stopping ART would be associated with poorer neuro-
cognitive function.
Methods: Neurocognitive function was assessed as part of ACTG 5170, a multicenter, prospec-
tive observational study of HIV-infected subjects who elected to discontinue ART. Eligible sub-
jects had CD4 count 350 cells/mm3, had HIV RNA viral load 55,000 cp/mL, and were on ART
(2 drugs) for 6 months. Subjects stopped ART at study entry and were followed for 96 weeks
with a neurocognitive examination.
Results: A total of 167 subjects enrolled with a median nadir CD4 of 436 cells/mm3 and 4.5 median
years on ART. Significant improvements in mean neuropsychological scores of 0.22, 0.39, 0.53, and
0.74 were found at weeks 24, 48, 72, and 96 (all p  0.001). In the 46 subjects who restarted ART
prior to week 96, no significant changes in neurocognitive function were observed.
Conclusion: Subjects with preserved immune function found that neurocognition improved signif-
icantly following antiretroviral treatment (ART) discontinuation. The balance between the neuro-
cognitive cost of untreated HIV viremia and the possible toxicities of ART require consideration.
Classification of evidence: This study provides Class III evidence that discontinuing ART is associ-
ated with an improvement in 2 neuropsychological tests (Trail-Making Test A & B and the Wech-
sler Adult Intelligence Scale–Revised Digit Symbol subtest) for up to 96 weeks. Resuming ART
was not associated with a decline in these scores for up to 45 weeks. Neurology® 2010;74:
1260 –1266
GLOSSARY
ACTG  AIDS Clinical Trials Group; ART  antiretroviral treatment; EFV  efavirenz; HAART  highly active antiretroviral ther-
apy; HAD  HIV-associated dementia; NP  neuropsychological summary score; TI  treatment interruption; VL  viral load.
HIV enters the CNS within days of infection, and can result in nervous system disease includ-
ing HIV-associated dementia (HAD) and the less severe dysfunction mild neurocognitive
disorder. Antiretroviral therapy (ART) has led to prolonged survival in patients with HIV,1-3
and a dramatic decrease in the incidence of HAD.4
In the past, many HIV-positive patients with preserved immune function were prescribed
ART, consistent with treatment guidelines at the time.5-7 After the recognition that ART led to
significant toxicities and did not eradicate latent HIV infection, updated guidelines recom-
mended delayed treatment initiation.8,9 There are conflicting results as to whether these pa-
tients can safely discontinue ART.10-12
Studies have shown that cognitive deficits are associated with ongoing viral replication in the
CNS and that neurocognitive functioning improves in patients who initiate ART.13-18 This
recovery of function suggests that the underlying mechanism includes an alteration of neuronal
e-Pub ahead of print on March 17, 2010, at www.neurology.org.
From the University of North Carolina (K.R.R., D.M.M.), Chapel Hill; Harvard School of Public Health (Z.S., A.K., S.E.), Boston, MA; University
of California (D.V.H.), San Francisco; and Baystate Medical Center (D.J.S.), Springfield, MA.
Study funding: Supported in part by the NIH/NIAID (AI-68636 to AIDS Clinical Trials Group and AI068634 to the Statistical and Data
Management Center) and by the General Clinical Research Center Units funded by the National Center for Research Resources.
Disclosure: Author disclosures are provided at the end of the article.
Presented in part at the 14th Conference on Retroviruses and Opportunistic Infections, Oral Abstract 113, Los Angeles, CA, February 25–28, 2007.
Editorial, page 1248
Address correspondence and
reprint requests to Dr. Kevin R.
Robertson, Department of
Neurology, University of North
Carolina, 2128 Physician Office
Building, 170 Manning Drive,
Chapel Hill, NC 27599-7025
kevinr@neurology.unc.edu
1260 Copyright © 2010 by AAN Enterprises, Inc.
function prior to actual cell death. Since CNS
viral replication is known to occur from the
initial days of infection, it is likely that neuro-
nal function is being impaired in the long
asymptomatic period of HIV infection, re-
sulting in subclinical cognitive impairment.
Since neurocognitive functioning improves
with ART, we hypothesized that neurocogni-
tion would get worse in patients who discon-
tinue treatment. We sought to evaluate
neurocognitive functioning after treatment
interruption (TI) in a population who had
early treatment initiation. We also sought to
evaluate potential neurocognitive improve-
ment on ART in those patients who resumed
ART, following a TI.
METHODS AIDS Clinical Trials Group (ACTG) 5170 was a
multicenter, observational, prospective, 2-step study in asymp-
tomatic HIV-infected subjects who wished to discontinue ART
in the United States.11 In step 1, eligible subjects elected to stop
antiretroviral therapy; in step 2, patients from step 1 reinitiated
antiretroviral therapy. This study design provided a Class III
level of evidence.
Standard protocol approvals, registrations, and patient
consents. This study, ACTG A5170, is registered with Clini-
calTrials.gov under the identifier NCT00050284. The study
was approved by the institutional review boards at each site. All
subjects gave written consent prior to enrollment.
Subjects. Subjects were included for step 1 if they had con-
firmed HIV-1 infection, age 12 years, CD4 count 350 cells/
mm3 immediately prior to first ART, CD4 count 350 cells/
mm3 and plasma HIV-1 RNA viral load (VL) 55,000
copies/mL at screening, currently receiving ART with 2 drugs
for 6 months, and a Karnofsky score 70. Subjects were ex-
cluded if they had a prior Centers for Disease Control and Pre-
vention category B or C event, active drug or alcohol use, or
serious medical condition that would negatively impact partici-
pation in the protocol. Complete inclusion and exclusion criteria
have been reported in the primary study report.11
Study design. Subjects who underwent TI upon entry to step 1
were followed for up to 96 weeks. Neurocognitive assessments were
conducted every 24 weeks. Subjects were eligible for step 2 if subject
or provider desired to reinitiate ART, and were followed for at least
24 weeks, or 96 weeks from step 1 entry (whichever was longer).
The protocol strongly recommended that subjects resume ART if
the CD4 cell count fell to 250 cells/mm3.
The neurocognitive examination consisted of Trail-Making
Test A & B19 and the Wechsler Adult Intelligence Scale–Revised
Digit Symbol subtest.20 These tests are sensitive in detecting both
HIV-related neurocognitive changes21,22 and antiretroviral effects
upon CNS functions.13 The raw test score of each measurement
was standardized using demographic-adjusted normative means,
which adjust for gender, age, education, and ethnicity (Cauca-
sian and African American).23 A standardized z score was calcu-
lated by subtracting the appropriate normative mean from the
raw score then dividing by the appropriate normative SD for
each test. A neuropsychological summary score (NP) was created
for the analyses, by averaging the z scores across the 3 tests.
Neurocognitive impairment was defined as 1 SD below the
mean on 2 of the 3 tests or 2 SDs below the mean on 1 of 3 tests.
Sustained impairment required subjects to meet the impairment
criteria for 2 consecutive visits.
The changes in NP score from the baseline to weeks 24, 48,
72, and 96 in step 1 and step 2 were analyzed using t test for
paired data. The linear and quadratic trends of the NP scores in
both steps were examined using generalized estimating equation
embedded in SAS PROC GENMOD procedure (Cary, NC).
To take into account the practice effect and possible informative
dropout, study week and the dropout time were included in the
regression model as covariates.24 In addition, 2 sensitivity analy-
ses were performed using the t test for paired data. In one analy-
sis, we compared the change in NP score after week 48 when the
practice effect was considered to be leveled out. In the other
analysis, we repeated the above analyses by only including sub-
jects who completed the 96 weeks of follow-up without resump-
tion of ART. Subgroup analyses assessing the effect of efavirenz
(EFV) (Sustiva, Princeton, NJ, Bristol-Myers Squibb), ABC
(Ziagen, GSK, RTP, NC), ZDV (Retrovir, GSK), D4T (Zerit,
BMS, New York, NY), and baseline HIV RNA category (50
cps/mL vs 50 cps/mL) in step 1 were performed. All tests were
2-sided. The p values were not adjusted for multiple tests and
p  0.05 was considered significant.
RESULTS Study population. Demographics charac-
teristics of the 167 subjects enrolled are presented in
tables 1 and 2. The median duration of ART prior to TI
was 4.5 years, and the median duration of follow-up
was 96 weeks after TI and 45 weeks after reinitiation of
ART. A total of 144 subjects completed the study, in-
cluding 102 who remained off ART for 96 weeks. A
total of 137 (82%) subjects had VL 400 copies/mL at
entry. The immunologic and virologic outcomes are de-
tailed elsewhere.11
Improved neurocognition when stopping antiretrovi-
rals. Mean NP scores increased when subjects
stopped ART (figure 1). Significant mean NP score
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improvements of 0.22, 0.39, 0.53, and 0.74 were
found at weeks 24, 48, 72, and 96 (all p  0.001)
(see table 3). The effect sizes (d) associated with the
observed changes ranged from medium (0.37 at 24
weeks) to large (1.08 at 96 weeks). Sensitivity analy-
sis including only the 95 subjects who stayed in step
1 for 96 weeks gave similar results.
Subsequent analyses were undertaken to better
understand the unexpected results. Practice or learn-
ing effects are known to occur with test-retest in neu-
rocognitive studies, tend to diminish with repeated
testing, and level out at the third repeated assess-
ment.24 Therefore, analyses were undertaken that ex-
amined changes at the third assessment on (48 weeks
and after). From week 48 to 72, the 107 subjects had
NP score improvements of 0.11 (p  0.05); from
week 48 to 96, the 95 subjects had NP score im-
provements of 0.33 (p  0.0001). Practice or learn-
ing effect does not seem to account for the improving
performance off antiretroviral therapy.
No neurocognitive improvements with ART resump-
tion. Forty-two subjects restarted ART and enrolled
in step 2. There were no significant improvements in
NP scores (figure 2). From ART resumption to week
24 on ART, NP scores improved 0.08 in the 37 sub-
jects with data available; at week 48 of ART resump-
tion, the mean improvement in NP scores was 0.09
in the 25 subjects still on study; at week 72 of ART
resumption, NP scores decreased by 0.06 in the 10
subjects still on study; and at week 96 of ART re-
sumption, the mean improvement in NP scores was
0.48 in the four subjects still on study at that time.
Neurocognitive impairment. For subjects stopping an-
tiretroviral therapy (step 1), 68 out of 166 with baseline
results were impaired (41%). There were 41 of 167
(25%) subjects with sustained impairment at some
point during step 1. There were 40 out of 166 with
impairment at baseline but who later became unim-
paired on step 1 (24%). For subjects who resumed ART
on step 2, 9 out of 39 subjects were impaired at baseline
(23%). There were 9 of 41 with sustained impairment
at some point during step 2 (22%). There were 3 out of
39 with impairment at step 2 baseline but who later
became unimpaired (8%).
Informative dropout. We were concerned that poten-
tial dropout of impaired subjects during step 1 cre-
ated the appearance of improved neurocognitive
scores over the course of step 1. Therefore, we com-
pared the NP scores in step 1 between subjects who
stayed on step 1 for 96 weeks to those who later went
to step 2. Between-group comparisons at week 24,
48, and 72 found no significant differences between
these subjects (all p  0.17, data not shown, compar-
ison at week 96 was not done because of insufficient
data). This suggests that the increases in performance
were not due to informative dropout. Among the
subjects reinitiating ART, we also compared the
baseline NP scores at step 1 to the baseline NP scores
at step 2. Of the 39 subjects who had NP scores at
entry to both step 1 and step 2, there was a mean
Table 2 Disease and treatment characteristics
at baseline
Characteristics Values
Preentry CD4 cell count,
cells/mm3
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increase of 0.34 (p  0.001) at step 2 baseline com-
pared to step 1 baseline.
In the regression analysis that simultaneously mod-
eled the change in NP score and time of dropout using
generalized estimating equation, the time of dropout
was not significant in step 1, and was marginally signif-
icant in step 2. However, the dropout effect was esti-
mated to be 0.19 for every 24 weeks, suggesting that
subjects who dropped out of step 2 early had a greater
0.19 increase in NP score from baseline compared with
those who dropped out 24 weeks later.
Neurocognition and virologic/immune system out-
comes. To assess potential differences related to HIV
VL, we stratified the sample into those with baseline
HIV RNA below (n  89) and at or above 50
cps/mL (n  50). No differences in neurocognitive
functioning were found between the HIV RNA VL
groups at 24, 48, 72, or 96 weeks. Sensitivity analyses
restricting the sample to only those who completed
96 weeks off ART found similar results with no dif-
ferences over time between the 2 groups. To assess
the effect of immune system functioning, we strati-
fied the group by using the median nadir CD4 cell
count (436) into those below (n  70) and above
(n  69). Those below had mean lower NP scores
(0.29) at week 72 than those above the median
(0.69). In the sensitivity analyses restricting the sam-
ple to those who remained off ART for 96 weeks, we
found a trend only (p  0.08).
Neurocognition and EFV, ABC, ZDV, and D4T. Pre-
vious studies have found that neurocognitive side ef-
fects were associated with the use of EFV.25 We
stratified the sample by EFV use to see if there were
differences in neurocognitive improvement between
the groups. Significant increases were noted in both
subgroup analyses of subjects discontinuing EFV-
containing regimens (baseline n  40; NP 0.77)
and non-EFV-containing regimens (baseline n 
126; NP 0.62). For the non-EFV group subjects,
the mean NP score improved 0.14, 0.34, 0.50, and
0.67 over weeks 24, 48, 72, and 96 (p  0.05); and
for the EFV group subjects, the mean NP score im-
proved 0.38, 0.59, 0.77, and 0.96 over weeks 24, 48,
72, and 96 (p  0.001). The difference in mean NP
scores between the 2 groups was significant (p 
0.024, Wei-Johnson test). Although there was some
evidence of greater neurocognitive improvement in
subjects discontinuing EFV-based regimens, both
EFV and non-EFV groups showed significant in-
creases in mean neurocognitive scores at each week
compared to baseline. Similar analyses for subgroups
who reported stopping ZDV (n  74) and those not
on ZDV (n  65); stopping D4T (n  49) and
those not (n  90); and stopping ABC (n  36) and
those not (n  103) did not find differences in neu-
rocognitive functioning over weeks 24, 48, 72, and
96 between these subgroups.
DISCUSSION HIV enters the CNS within days of
initial infection, and is resident within the CNS
throughout the prolonged asymptomatic period of
HIV infection. CNS damage is thought to be associated
with HIV viremia and inflammatory responses.26,27
It is known that highly active antiretroviral ther-
apy (HAART) improves neurocognitive fun-
ctioning.13,14,28-30 We expected that neurocognitive
functioning would become worse when patients
stopped taking antiretroviral therapy. Contrary to
our hypothesis, neurocognitive functioning signifi-
cantly improved after patients stopped treatment.
This improvement continued over the course of the
96-week follow-up of the study among the patients
remaining off ART. Based on the effect sizes, the
magnitude of the observed improvement is likely to
be clinically meaningful.
Why might this have occurred in this healthy
population stopping antiretroviral therapy? There are
several potential explanations. It is possible that these
Figure 1 Plot of mean neuropsychological summary score following
treatment interruption
Table 3 Change in NP scores from baseline after TI (step 1) and ART
resumption (step 2)
Step Week Mean No. SD t Test p
1 24 0.22 139 0.59 4.41 0.0001
1 48 0.39 131 0.64 7.04 0.0001
1 72 0.53 110 0.76 7.25 0.0001
1 96 0.74 95 0.68 10.55 0.0001
2 24 0.08 37 0.51 0.95 NS
2 48 0.09 25 0.46 0.98 NS
2 72 0.06 10 0.50 0.36 NS
2 96 0.48 4 0.84 1.13 NS
Abbreviations: ART  antiretroviral therapy; NP score  neuropsychological summary
score; TI  treatment interruption.
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patients had subtle CNS drug-related toxicity that
improved when treatment was stopped. It is known
that repeated neuropsychological assessment can re-
sult in practice or learning effects, where improve-
ment in functioning is due to practice or learning.
However, studies have shown that practice or learn-
ing effects level off after 3 assessments.24 We assessed
whether the observed improvement could be attrib-
uted to practice or learning effects. We observed con-
tinued improvement from 48 weeks out (third
testing) on the study, indicating that the improve-
ments are not likely to be solely attributed to practice
or learning effects. It is possible that the follow-up
period on study was not long enough to document
changes. However, this seems unlikely since the me-
dian duration of follow-up was 96 weeks, a duration
4 times longer than those associated with improve-
ment when starting antiretrovirals. Although un-
likely, it is possible that prior antiretroviral regimens
did not have benefit on the CNS. Antiretrovirals
thought to enter the CNS were widely represented in
the baseline ART regimens.28 It is also possible that
there was a patient selection bias, so that subjects
who elected to stop antiretrovirals were somehow
more likely to have neurocognitive improvement. It
may also be that the brief neuropsychological battery
was not sensitive enough to detect declines. How-
ever, significant improvements were detected, indi-
cating that the battery was sensitive enough in this
study. Although brief, these tests have been found to
be sensitive21,22 and specific31 in detecting HIV-
related neurocognitive changes.
We also noted a lack of substantial neurocognitive
improvement with resumption of ART. Neurocogni-
tive improvement with initiation of HAART has been
documented in many studies of patients who were naïve
or failing current therapy. However, these studies were
of patients who initiated treatment later in the disease
course. Patients later in the disease may have greater
inflammation within the CNS, or greater VL, and ther-
apeutic intervention may have a greater benefit. As the
virus is present in the CNS early in the disease process,
it is likely that a threshold of neuronal damage must be
reached for subclinical and clinical findings to be de-
monstrable. Once the viral replication has exceeded this
threshold, clinical findings are readily apparent. Early in
disease, cognitive reserves may allow for continued
near-normal functioning. Treatment initiation at this
early stage of disease may not result in the acute cogni-
tion gains that have been found with treatment at later
disease stages.32
There was fluctuation in the level of impairment
observed during this study. At baseline, 41% of the
subjects were impaired, the majority of whom (59%)
later became unimpaired. Twenty-five percent of
subjects had sustained impairment off treatment at
some point, and a similar number (22%) of those
who resumed ART had sustained impairment at
some point. These findings are similar to a much
larger study, the ACTG Linked Longitudinal Ran-
domized Trial, which utilized the same brief neuro-
psychological battery and assessed 1,160 subjects.33 It
is well-known that there are cognitive side effects of
EFV,25 which could have played a role in this study.
Due to these cognitive side effects, those subjects on
EFV regimens might be expected to have greater
neurocognitive improvement than those with non-
EFV regimens. We investigated the potential cogni-
tive side effect implications for this study by
stratifying subjects into those who had been on an
EFV-containing regimen vs those who had not.
When comparing between the EFV and non-EFV
groups, we found that the EFV group had greater
improvement than the non-EFV group. We also
found that both groups had significant cognitive im-
provement at all time points after discontinuing anti-
retroviral treatment. When other agents with
possible impact on the CNS such as ZDV, ABC, and
D4T were analyzed, there were no differences be-
tween groups who stopped regimens with these
agents over time. We also investigated the relation-
ship of VL and immune functioning to neurocogni-
tion in these patients as they stopped treatment. We
found no relationship between neurocognitive func-
tioning and baseline VL. There was a relationship
with nadir CD4, but only at one time point.
There are several limitations to the present study
that could be addressed in future studies investigat-
ing neurocognition and treatment interruption. We
were unable to include an HIV untreated control
group with similar disease severity in the current
study, which may have allowed a more precise deter-
mination of the practice/learning effects. We did not
assess for depression, anxiety, or substance abuse, al-
Figure 2 Plot of mean neuropsychological summary score following
treatment resumption
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though these were exclusionary criteria at diagnostic
levels. We found improved neurocognitive function-
ing in this unique cohort of subjects who initiated
antiretroviral treatment prior to immune impair-
ment, and then later discontinued therapy. We were
not able to attribute these results to practice and
learning effects or the selective reinitiation of ART. It
is possible that subtle antiretroviral toxicity may un-
derlie the improvements measured after ART was
stopped. Contrary to prior studies, significant neuro-
cognitive improvement was not observed with re-
sumption of ART in this unique cohort. This lack of
observed improvement may be related to the earlier
initiation of ART, where benefits occurred in other
studies at a later disease stage, but may also be due to
limited power. With the recent suggestion that ear-
lier initiation of ART may improve clinical out-
comes, the effect of ART as compared to that of
unchecked HIV replication on neurocognitive func-
tion will require careful prospective study.34
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